SUMMARY Hemodynamic monitoring after a single dose (10 mg) of nifedipine in 27 primary hypertensive subjects (diastolic pressure > 110 mm Hg) documented that this calcium antagonistic agent exerts a potent arteriolar vasodilating action, which results in prompt (-21% of control at 30 minutes) and persistent (-16% of control at 120 minutes) fall in mean arterial pressure associated with a rise in cardiac output and pulse rate.
HIGH VASCULAR RESISTANCE is the proximate cause of elevated arterial pressure in most patients with chronic hypertension. Blood pressure can be normalized either by decreasing cardiac output or by lowering vascular resistance. The former, however, makes circulation doubly abnormal, since vascular resistance remains excessive and cardiac output becomes abnormally low. This situation may be associated-with tissue hypoperfusion, involving kidneys, heart and brain. The desired hemodynamic effect in antihypertensive therapy is dilatation of constricted arterioles by a compound that acts directly on the smooth muscle, relaxes arterioles independently of the vasoconstrictor mechanism, and does not affect the heart or decrease the venous return.
Hydralazine, diazoxide, minoxidil and guancydine act directly on vascular smooth muscle to produce vasodilatation, and were introduced with variable degrees of success in the chronic treatment of hypertension. These agents share several common side effects, including an exaggeration of cardiac action that may precipitate angina pectoris in patients with coronary disease and the promotion of renin release, sodium retention and plasma volume expansion. In most circumstances ,B-blockers and diuretics should be added to counteract these effects.' 3 The cellular mechanism of vasodilatation is not yet understood, but the capacity to chelate certain trace metals required for smooth-muscle contraction has been suggested as the vasodilating mechanism of diazoxide4 and hydralazine.5 A distinct group of compounds, the so-called calcium antagonists, specifically inhibit the penetration of extracellular calcium through the cell membrane and the inflow of Ca++ ions from the binding sites of the sarcoplasmatic reticulum into the cell plasma, where the ATPase of the myofibrils is located. This enzyme needs Ca++ ions to be activated and to split ATP for the energydelivering process of muscle contraction. The reduction of the contractile activity of the heart as well as the coronary and systemic vasodilatation brought about by the calcium antagonistic compounds6-10 provide the rationale for their use in the management of angina pectoris. Since systemic vasodilatation can be expected to lower elevated blood pressure, during the last few years interest has been focused on calcium antagonists in the medical treatment of hypertension.'" Recently, we reported that the profound vasodilating action of nifedipine [4- fig. 1 ), a calcium antagonistic agent, has a considerable antihypertensive effect.12 In view of the promptness and the magnitude of the hypertensive reaction, we proposed its use for treating emergencies of severe hypertension.
The present study evaluates the chronic use of nifedipine in the therapeutic management of sustained hypertension. The well-documented antianginal action'13'7 seems to offer a desirable advantage.
Materials and Methods
Twenty-seven hospitalized men, average age 52 years, were admitted to the study after fulfilling the American Heart Association."' All blood pressures were taken three times at 1-minute intervals in the supine position and, subsequently, in the standing position, at least 5 minutes after the change in posture. Results of the three determinations were averaged. Pulse rate was counted after the last pressure recording in each position. Body weight and urinary output were checked daily. Blood urea nitrogen, serum creatinine and electrolyte concentration, glomerular filtration rate, plasma volume (dilution of T-1824) and plasma renin activity, both in the supine and, after 2 hours, standing positions, were determined at the end of the run-in and trial periods. The patients were on a standard 100 mEq sodium diet. Plasma renin activity was measured by radioimmunoassay'9 of angiotensin I in plasma venous samples and calculated as the difference between immunoreactive angiotensin I formed during 3-hour plasma incubation at 37°C and that present in an unincubated plasma sample at 4°C. It was expressed as nanograms of angiotensin I formed per milliliter of plasma per hour.
For the hemodynamic measurements a #5 flowdirected Swan-Ganz catheter was inserted percutaneously, under local anesthesia, into an antecubital vein and floated, under fluoroscopy, to the pulmonary artery or advanced to the wedge position. A polyethylene radiopaque catheter, introduced percutaneously into a brachial artery and advanced to the thoracic aorta, was used to monitor arterial pressure and to sample blood for cardiac output. Reproducible dye dilution curves were obtained by a Gilford densitometer after rapid injection of indocyanine green dye (5 mg) into the main pulmonary artery just beyond the pulmonary valve. Pressures were determined with Statham P23De and P23Db strain gauge transducers and recorded on a Gould-Brush eightchannel ink recorder, model 480. The zero reference level for pressure recording was 5 cm below the sternal angle. The mean pressures were obtained by electronic damping. Systemic vascular resistance (SVR) and pulmonary arteriolar resistance (PAR), in dyn-seccm-5, were calculated from the following formulas:
AP -RAP X 1332 X 60 CO (ml/min) PAR = PAP -PWP X 1332 X 60 CO (ml/min) where AP is mean systemic arterial pressure, PAP is mean pulmonary arterial pressure, RAP is mean right atrial pressure, PWP is mean pulmonary wedge pressure and CO is cardiac output.
For the analysis of the circulatory data, differences were assessed through the analysis of variance, with an Olivetti desk-top computer.
Results
The time course of the circulatory response to a 10-mg oral dose of nifedipine in the whole hypertensive group is shown in figure 2. Average changes from control of mean systemic and pulmonary arterial (fig. 3) . Figure 4 reports the averages of the daily sphygmomanometric systolic and diastolic readings in groups 1 and 2 during placebo (days 1-10, and again after day 29) and trial (days [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Open arrows indicate placebo; solid arrows indicate active compound. A indicates differences from the corresponding value on day 10 significant at p 0.05; *differences from the corresponding value on day 10 significant at p < 0.01. reverted to control values, while the cardiac output remained elevated.
No correlation was found between cardiac output, during either baseline or hypotensive phases, and the magnitude of the blood pressure fall. There was, however, a correlation between vascular resistance in the control state and hypotensive response to nifedipine, suggesting that, within certain limits, the greater the vasoconstriction the greater the hypotensive effect of the drug, and also that modulation of this effect depends not so much upon the cardiac output reaction as upon the degree of vasodilatation. In spite of the augmented flow, pulmonary pressure did not increase. Whether this was a consequence of a direct vasodilating effect of the compound or of the high compliance of the pulmonary vascular bed, is not known.
Throughout chronic treatment nifedipine maintained its ability to lower blood pressure, as it did during acute hemodynamic monitoring in both groups. 
